Navigation Links
Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: a randomized controlled trial. Lancet. 2004; 364(9435): 675-684. 11. Schnitzer T, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: a randomized controlled trial. Lancet. 2004; 364(9435): 665-674.

# # #

Novartis Media Relations

Corinne Hoff Irina Ferluga Novartis Global Media Relations Novartis Pharma Communications +41 61 324 9577 (direct) + 41 61 324 2422 (direct) +41 79 248 5717 (mobile) + 41 79 824 1121 (mobile) corinne.hoff@novartis.com irina.ferluga@novartis.com

e-mail: media.relations@novartis.com

Novartis Investor Relations

International Ruth Metzler-Arnold +41 61 324 7944 Katharina Ambühl +41 61 324 5316 Nafida Bendali +41 61 324 3514 Jason Hannon +41 61 324 2152 Thomas Hungerbuehler +41 61 324 8425 Richard Jarvis +41 61 324 4353

North America Ronen Tamir +1 212 830 2433 Jill Pozarek +1 212 830 2445 Edwin Valeriano +1 212 830 2456

e-mail: investor.relations@novartis.com


'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:6/29/2015)... , June 29, 2015 BiondVax ... preliminary results from its BVX-006 Phase II clinical trial ... In this trial, M-001 was injected intramuscularly to volunteers ... an administration of the 2014/15 season trivalent influenza vaccine ... safe and well tolerated and induced humoral immune responses, ...
(Date:6/29/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Russell 1000 Index, effective June 26, 2015. The Russell ... of the U.S. equity universe. It is a subset ... of the largest securities based on a combination of ... "We are pleased to be added to this important ...
(Date:6/29/2015)... SAN JOSE, Calif. , June 29, 2015 ... its expert medical workstation lineup. The high-powered, multi-functional ... th generation Intel® Haswell Core ... processor. Both provide significant data processing and computing ... visual performance, making the unit well suited for ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
(Date:6/30/2015)... ... 2015 , ... This Fourth of July, Peacock Alley celebrates the ... work, tenacity, perseverance, commitment to quality, honesty and love of friends and family. These ... Gabler's simple love of quilts, Peacock Alley was fully realized and grown while raising ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Curly Hair ... 14, the largest beauty event in the US, featuring products from all over the ... Keeper™ Collection. The Collection is a line of hair styling products focused entirely on ...
(Date:6/29/2015)... City, NY (PRWEB) , ... June 30, 2015 ... ... honors Melanie Richards as a 2015-2016 inductee into its VIP ... leadership in business. NAPW is the nation’s leading networking organization exclusively for professional ...
(Date:6/29/2015)... ... June 30, 2015 , ... Leaders ... one of the industry’s premier thought leadership symposiums, “Harmony 2015” hosted by Massachusetts-based ... rehabilitation managers and other management and corporate personnel representing the skilled nursing and ...
(Date:6/29/2015)... ... ... The United States Equestrian Federation (USEF) is pleased to announce a ... Occupational Therapists of the U.S. Eventing Team. KORT also provided the official onsite ... , “The USEF is pleased to welcome the Kentucky Orthopedic Rehab Team as the ...
Breaking Medicine News(10 mins):Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:Curly Hair Solutions™ Showcases Entire Curl Keeper™ Collection at Cosmoprof Las Vegas July 12 - 14 2Health News:National Association of Professional Women Inducts Melanie Richards, DMD, of Powdersville Pediatric Dentistry, Into its VIP Woman of the Year Circle 2Health News:Gov. Mark Parkinson, President and CEO of AHCA/NCAL to Give Keynote Address at Harmony 2015 2Health News:Gov. Mark Parkinson, President and CEO of AHCA/NCAL to Give Keynote Address at Harmony 2015 3Health News:KORT Physical Therapy Announces Partnership with The United States Equestrian Federation 2
... Practicing Clinicians Exchange (PCE) has formed a ... to provide continuing education programs to nurse practitioners ... States.The partnership capitalizes on the strengths of both ... advocacy and research in RLS, and PCE is ...
... Genoptix, Inc. (Nasdaq: GXDX ), a specialized ... Bank of America and Merrill Lynch 2009 Annual Health Care ... City on May 12 - 14, 2009. Sam Riccitelli, ... on Tuesday, May 12, 2009 beginning at approximately 8:00 a.m. ...
... Driven by Improved Margins and Higher Sales of Select ... Companies, Inc. (NYSE: PRX ) today reported ... Par reported total revenues of $204.0 million and net ... which included a change in estimate relating to the ...
... in U.S. dollarsQUEBEC CITY, May 6 /PRNewswire-FirstCall/ - AEterna ... ("the Company"), a global biopharmaceutical company focused on endocrinology ... at and for the three months ended March 31, ... Signing of partnership with sanofi-aventis for cetrorelix ...
... Carriage Services, Inc. (NYSE: CSV ) today announced ... Merrill Lynch 2009 Health Care Conference to be held May ... Melvin Payne, Chief Executive Officer, and Terry Sanford, Chief ... 2009 at 4:00 p.m. eastern time. The live webcast ...
... from hearing loss. Hearing aids often cost thousand of dollars per pair ... money on over-the-counter hearing aids starting at under $400 and includes a ... ... -- May is Better Hearing and Speech month and according to ...
Cached Medicine News:Health News:Practicing Clinicians Exchange Forms Partnership With Restless Legs Syndrome Foundation 2Health News:Practicing Clinicians Exchange Forms Partnership With Restless Legs Syndrome Foundation 3Health News:Genoptix Announces Participation at the Bank of America and Merrill Lynch 2009 Annual Health Care Conference 2Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 2Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 3Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 4Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 5Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 6Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 7Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 8Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 9Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 10Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 11Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 2Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 3Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 4Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 5Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 6Health News:AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results 7Health News:In Time for Better Hearing and Speech Month: VidaCura.com and Nexear Offers Consumers an Alternative to Traditional Costly Hearing Aids 2Health News:In Time for Better Hearing and Speech Month: VidaCura.com and Nexear Offers Consumers an Alternative to Traditional Costly Hearing Aids 3
... curtains or parting strip shields ... frame to form a free-standing, ... cleanliness to Class 10/ISO 3. ... lights, and ionizers are configured ...
Inquire...
Inquire...
Inquire...
Medicine Products: